Europe Ophthalmic Drugs Market Size (2021 to 2026)
The European Ophthalmic Drugs market size is estimated to be worth USD 11.06 billion by 2026 and USD 8.71 billion in 2021, growing at a CAGR of 4.90% during the forecast period. It captures 25% of the global market share.
The rise in the prevalence of eye diseases such as glaucoma, cataract, macular degeneration, and the spike in demand for ophthalmic medications and increased investment in R&D activities by various healthcare businesses are key factors driving the European ophthalmic drugs market. In addition, the market growth is expected to be driven by the increased laser procedures, digitalization of the workplace, rising incidence of eye-related illnesses and an aging population, increased burden of diabetes and other comorbidities, adverse effects of other medications, and a promising pipeline for dry eye disease. Hereditary ophthalmic diseases, neurovascular retinal abnormalities, and retinoblastoma benefit from gene therapy for diagnosis and treatment. As a result, further research is needed to optimize and broaden gene therapy's applicability across ophthalmic diseases. In recent years, drug delivery methods in ophthalmic treatment have seen significant technical advancements, expected to boost the market's growth.
Various market participants are progressively focused on creating novel therapies, and the European ophthalmology drug and device market is projected to increase significantly in the next few years. The market is likely to be driven in the future by a significant number of eye disorders, the availability of new and advanced technology, and patient desire for non-invasive treatment. Furthermore, ophthalmic pharmaceutical firms are pursuing strategic initiatives like collaborations, acquisitions, and partnerships to extend their product pipeline with new clinical-stage opportunities, which is expected to boost the market.
However, the significant risk involved with eye surgery and strict restrictions may limit the expansion of the European ophthalmic drugs market during the forecast period. In addition, long and costly drug approval procedures, insufficient insurance coverage of ophthalmologists' services, the expiration of branded drug patents, and disruption in the supply chain of ophthalmology drugs due to the impact of covid-19 are factors that could slow the growth of the European ophthalmology drugs market.
During the forecast period, market growth is further estimated to be challenged by the time factor it takes to manufacture and manufacture ophthalmic drugs and the adverse effects associated with them. In addition, the ophthalmology business has a significant challenge in the form of a lack of health insurance among the public or insurance that includes all types of IOLs or contact lenses in this nation. The rising cost of healthcare and the FDA’s strict guidelines for drug clearance limit the market's expansion.
This research report on the European ophthalmic drugs market has been segmented and sub-segmented into the following categories:
By Therapeutic Class:
- Anti-inflammatory Drugs
- Anti-infective Drugs
- Anti-glaucoma Drugs
- Anti-allergy Drugs
- Anti-VEGF Agents
- Others
By Product Type:
- Prescription Drugs
- Over-the-Counter Drugs
By Distribution Channel:
- Hospital Pharmacies
- Online Pharmacies
- Independent Pharmacies
- Drug Stores
By Disease Indications:
- Dry Eye
- Glaucoma
- Infection/Inflammation
- Retinal Disorders
- Allergy
- Uveitis
- Others
By Dosage Form:
- Liquid Ophthalmic Drug Forms
- Solid Ophthalmic Drug Forms
- Semisolid Ophthalmic Drug Forms
- Multicompartment Drug Delivery Systems
- Other Ophthalmic Drug Forms
By Technology:
- Biologics
- Cell Therapy
- Gene Therapy
- Drug Delivery
- Small molecule
- Others
By Country:
- UK
- France
- Spain
- Germany
- Italy
- Russia
- Sweden
- Denmark
- Switzerland
- Netherlands
- Turkey
- Czech Republic
- Rest of Europe
Regionally, the European ophthalmic drugs market was the second-largest regional market in the global market in 2020; however, it is likely to undergo sluggish growth till 2026. Europe is the second-largest market for ophthalmic drugs. The major potential for regional market growth is increased awareness of ophthalmic medicines in the region. The rising frequency of eye disease and the expanding elderly population are some of the reasons driving the market's growth. Cataract surgery is one of the most prevalent surgical procedures in Europe. The rising number of cataract operations has significantly influenced the ophthalmic industry, resulting in increased demand for cataract surgery equipment and medicines. Additionally, increased awareness of the prevention and treatment of eye disease and increased demand for advanced healthcare facilities are driving the market forward. Among various countries of Europe, the France ophthalmic drugs market is expected to play a leading role during the forecast period.
KEY MARKET PLAYERS:
A few noteworthy companies operating in the European ophthalmic drugs market profiled in this report are Carl-Zeiss AG, Ellex Medical Lasers Ltd., Hoya Corporation, Novagali Pharma S A, Abbott Medical Optics, Inc., Essilor International S.A. Other players in the market include Insight Vision Inc., Nidek Co.Ltd, Topcon Corporation, and Ziemer Ophthalmic Systems AG.
- Introduction
- Market Definition
- Study Deliverables
- Base Currency, Base Year and Forecast Periods
- General Study Assumptions
- Research Methodology
- Introduction
- Research Phases
- Secondary Research
- Primary Research
- Econometric Modelling
- Expert Validation
- Analysis Design
- Study Timeline
- Overview
- Executive Summary
- Key Inferences
- Epidemology
- Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
- Market Drivers
- Market Restraints
- Key Challenges
- Current Opportunities in the Market
- Market Segmentation
- Therapeutic Class
- Introduction
- Anti-inflammatory Drugs
- Nonsteroidal Anti-inflammatory Drugs
- Steroids
- Anti-infective Drugs
- Anti-fungal Drugs
- Anti-bacterial Drugs
- Others
- Anti-glaucoma Drugs
- Alpha Agonist
- Beta Blockers
- Prostaglandin Analogs
- Combined Medication
- Others
- Anti-allergy Drugs
- Anti-VEGF Agents
- Others
- Y-o-Y Growth Analysis, By Therapeutic Class
- Market Attractiveness Analysis, By Therapeutic Class
- Market Share Analysis, By Therapeutic Class
- Product Type
- Introduction
- Prescription Drugs
- Over-the-Counter Drugs
- Y-o-Y Growth Analysis, By Product Type
- Market Attractiveness Analysis, By Product Type
- Market Share Analysis, By Product Type
- Distribution Channel
- Introduction
- Hospital Pharmacies
- Online Pharmacies
- Independent Pharmacies & Drug Stores
- Y-o-Y Growth Analysis, By Distribution Channel
- Market Attractiveness Analysis, By Distribution Channel
- Market Share Analysis, By Distribution Channel
- Disease Indications
- Introduction
- Dry Eye
- Glaucoma
- Infection/Inflammation
- Retinal Disorders
- Wet Age-related Macular Degeneration
- Dry Age-related Macular Degeneration
- Diabetic Retinopathy
- Others
- Allergy
- Uveitis
- Others
- Y-o-Y Growth Analysis, By Disease Indications
- Market Attractiveness Analysis, By Disease Indications
- Market Share Analysis, By Disease Indications
- Dosage Form
- Introduction
- Liquid Ophthalmic Drug Forms
- Solid Ophthalmic Drug Forms
- Semisolid Ophthalmic Drug Forms
- Multicompartment Drug Delivery Systems
- Other Ophthalmic Drug Forms
- Y-o-Y Growth Analysis, By Dosage Form
- Market Attractiveness Analysis, By Dosage Form
- Market Share Analysis, By Dosage Form
- Technology
- Introduction
- Biologics
- Cell Therapy
- Gene Therapy
- Drug Delivery
- Small molecule
- Others
- Y-o-Y Growth Analysis, By Technology
- Market Attractiveness Analysis, By Technology
- Market Share Analysis, By Technology
- Geographical Analysis
- Introduction
- Regional Trends
- Impact Analysis
- Y-o-Y Growth Analysis
- By Geographical Area
- By Therapeutic Class
- By Product Type
- By Distribution Channel
- By Disease Indication
- By Dosage Form
- By Technology
- Market Attractiveness Analysis
- By Geographical Area
- By Therapeutic Class
- By Product Type
- By Distribution Channel
- By Disease Indication
- By Dosage Form
- By Technology
- Market Share Analysis
- By Geographical Area
- By Therapeutic Class
- By Product Type
- By Distribution Channel
- By Disease Indication
- By Dosage Form
- By Technology
- U.K
- Spain
- Germany
- Italy
- France
- Strategic Analysis
- PESTLE analysis
- Political
- Economic
- Social
- Technological
- Legal
- Environmental
- Porter’s Five analysis
- Bargaining Power of Suppliers
- Bargaining Power of Consumers
- Threat of New Entrants
- Threat of Substitute Products and Services
- Competitive Rivalry within the Industry
- Market Leaders' Analysis
- Abbott Medical Optics, Inc.
- Overview
- Product Analysis
- Financial analysis
- Recent Developments
- SWOT analysis
- Analyst View
- Carl-Zeiss AG
- Ellex Medical Lasers Ltd.
- Essilor International S.A.
- Hoya Corporation
- Insight Vision Inc.
- Nidek Co.Ltd
- Novagali Pharma S A
- Topcon Corporation
- Ziemer Ophthalmic Systems AG.
- Competitive Landscape
- Market share analysis
- Merger and Acquisition Analysis
- Agreements, collaborations and Joint Ventures
- New Product Launches
- Market Outlook and Investment Opportunities
- Appendix
- List of Tables
- List of Figures
- Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
- Segment-level analysis in terms product type and Packaged Containers along with market size forecasts and estimations to detect key areas of industry growth in detail
- Identification of key drivers, restraints, opportunities and challenges (DROC) in the market and their impact on shifting market dynamics
- Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
- Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development
- A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
- Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
- An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
- Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
